PRFX PainReform Ltd. Stock Quote

PRFX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

Index	-	P/E	-	EPS (ttm)	-	Insider Own	23.10%	Shs Outstand	9.05M	Perf Week	-28.00%
Market Cap	34.79M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	0.00%	Shs Float	7.74M	Perf Month	2.13%
Income	-	PEG	-	EPS next Q	-0.51	Inst Own	44.90%	Short Float	1.26%	Perf Quarter	-8.86%
Sales	-	P/S	-	EPS this Y	-362.10%	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-36.28%
Book/sh	2.25	P/B	1.28	EPS next Y	26.50%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	1.61	P/C	1.79	EPS next 5Y	-	ROE	-	52W Range	2.18 - 7.85	Perf YTD	-35.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-63.31%	Beta	-
Dividend %	-	Quick Ratio	28.80	Sales past 5Y	-	Gross Margin	-	52W Low	32.11%	ATR	0.80
Employees	1	Current Ratio	28.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.96	Volatility	23.35% 26.03%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-117.20%	Profit Margin	-	Rel Volume	1.13	Prev Close	3.46
Shortable	No	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.52M	Price	2.88
Recom	2.00	SMA20	-5.76%	SMA50	-2.63%	SMA200	-29.72%	Volume	1,723,444	Change	-16.76%

Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? Insider Monkey -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate Simply Wall St.
May-13-21 08:15AM	PainReform Provides Business Update for the First Quarter of 2021 GlobeNewswire +5.58%
Mar-18-21 09:15AM	PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief GlobeNewswire -11.82%
Mar-11-21 10:43AM	PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference GlobeNewswire
Mar-08-21 09:00AM	PainReform Announces $6.0 Million Private Placement GlobeNewswire
Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations GlobeNewswire -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 ACCESSWIRE
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer ACCESSWIRE +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors ACCESSWIRE
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors ACCESSWIRE
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 ACCESSWIRE
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials ACCESSWIRE
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering ACCESSWIRE

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience